IPSEN (OTCMKTS:IPSEY) Sees Large Volume Increase – Time to Buy?

IPSEN (OTCMKTS:IPSEY) shares saw an uptick in trading volume on Monday . 5,114 shares changed hands during trading, an increase of 134% from the previous session’s volume of 2,190 shares.The stock last traded at $48.13 and had previously closed at $46.50.

Analysts Set New Price Targets

Several brokerages have recently commented on IPSEY. Zacks Research upgraded shares of IPSEN to a “hold” rating in a report on Friday, May 29th. HC Wainwright restated a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, IPSEN currently has an average rating of “Hold”.

IPSEN Stock Up 3.5%

The company’s 50 day moving average price is $47.13 and its 200 day moving average price is $44.10.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).